Hamadani, Mehdi
Mayo Clinic
CIBMTR® (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, WI, United States.
Citations 32
Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure
Smith, Sonali M. , Godfrey, James , Ahn, Kwang Woo , Digilio, Alessandro, Ahmed, Sairah , Bachanová, Veronika , Bashey, Asad, Bolaños‐Meade, Javier , Cairo, Mitchell S. , Chen, Andy , Copelan, Edward A. , Aljurf, Mahmoud , Farooq, Umar , Ganguly, Siddhartha , Holmberg, Leona , Inwards, David J. , Kanate, Abraham S. , Karmali, Reem , Kenkre, Vaishalee P. , Kharfan‐Dabaja, Mohamed A. , Klein, Andreas K. , Mei, Matthew , Geethakumari, Praveen Ramakrishnan , Saad, Ayman , Schouten, Harry C. , Shah, Nirav N. , Urbano-Ispizúa, Álvaro , Vij, Ravi , Sureda, Anna , Holmberg, Leona , Bachanova, Veronika , Inwards, David, Mussetti, Alberto , Savani, Bipin N , Sureda, Anna , Hamadani, Mehdi , Chen, Andy I. , Saad, Ayman , Mei, Matthew , Farooq, Umar , Ahmed, Sairah , Karmali, Reem , Agrawal, Vaibhav , Bacher, Ulrike , Chhabra, Saurabh , Dahi, Parastoo B , Hertzberg, Mark , Lazarus, Hillard M. , Mussetti, Alberto , Nishihori, Taiga , Savani, Bipin N. , Vose, Julie M. , Hamadani, Mehdi
Cancer | April 12, 2018 | Volume: 124 | Issue: 12 | Pages: 2541-2551
BACKGROUNDEarly treatment failure (ETF) in follicular lymphoma (FL), defined as relapse or progression within 2 years of frontline chemoimmunotherapy, is a newly recognized marker of poor survival and identifies a high‐risk group of patients with an expected 5‐year overall survival (OS) rate of approximately 50%. Transplantation is an established option for relapsed FL, but its efficacy in this specific ETF FL population has not been previously evaluated.METHODSThis study compared autologous hematopoietic stem cell transplantation (auto‐HCT) with either matched sibling donor (MSD) or matched unrelated donor (MUD) allogeneic hematopoietic cell transplantation (allo‐HCT) as the first transplantation approach for patients with ETF FL (age ≥ 18 years) undergoing auto‐HCT or allo‐HCT between 2002 and 2014. The primary endpoint was OS. The secondary endpoints were progression‐free survival, relapse, and nonrelapse mortality (NRM).RESULTSFour hundred forty FL patients had ETF (auto‐HCT, 240; MSD hematopoietic stem cell transplantation [HCT], 105; and MUD HCT, 95). With a median follow‐up of 69 to 73 months, the adjusted probability of 5‐year OS was significantly higher after auto‐HCT (70%) or MSD HCT (73%) versus MUD HCT (49%; P = .0008). The 5‐year adjusted probability of NRM was significantly lower for auto‐HCT (5%) versus MSD (17%) or MUD HCT (33%; P < .0001). The 5‐year adjusted probability of disease relapse was lower with MSD (31%) or MUD HCT (23%) versus auto‐HCT (58%; P < .0001).CONCLUSIONSPatients with high‐risk FL, as defined by ETF, undergoing auto‐HCT for FL have low NRM and a promising 5‐year OS rate (70%). MSD HCT has lower relapse rates than auto‐HCT but similar OS. Cancer 2018;124:2541‐51. © 2018 American Cancer Society.
Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis
Kumar, Shaji , Zhang, Mei-Jie , Li, Peigang , Dispenzieri, Angela , Krishnan, Amrita , Wirk, Baldeep , Weiss, Brendan M. , Freytes, César O. , Vogl, Dan T. , Vesole, David H. , Meehan, Kenneth R., Hamadani, Mehdi , Lill, Michael, Majhail, Navneet S. , Wiernik, Peter H. , Nath, Rajneesh , Kamble, Rammurti T., Vij, Ravi , Kyle, Robert A. , Hari, Parameswaran , Milone, Giuseppe , Lonial, Sagar , Maiolino, Ângelo , Lazarus, Hillard M. , Callander, Natalie S. , Gale, Robert Peter , Dispenzieri, Angela , Hamadani, Mehdi , Majhail, Navneet S , Hari, Parameswaran
Blood | June 21, 2011 | Volume: 118 | Issue: 7 | Pages: 1979-1988
Abstract Allogeneic hematopoietic cell transplantation in multiple myeloma is limited by prior reports of high treatment-related mortality. We analyzed outcomes after allogeneic hematopoietic cell transplantation for multiple myeloma in 1207 recipients in 3 cohorts based on the year of transplantation: 1989-1994 (n = 343), 1995-2000 (n = 376), and 2001-2005 (n = 488). The most recent cohort was significantly older (53% > 50 years) and had more recipients after prior autotransplantation. Use of unrelated donors, reduced-intensity conditioning and the blood cell grafts increased over time. Rates of acute graft-versus-host (GVHD) were similar, but chronic GVHD rates were highest in the most recent cohort. Overall survival (OS) at 1-year increased over time, reflecting a decrease in treatment-related mortality, but 5-year relapse rates increased from 39% (95% confidence interval [CI], 33%-44%) in 1989-1994 to 58% (95% CI, 51%-64%; P < .001) in the 2001-2005 cohort. Projected 5-year progression-free survival and OS are 14% (95% CI, 9%-20%) and 29% (95% CI, 23%-35%), respectively, in the latest cohort. Increasing age, longer interval from diagnosis to transplantation, and unrelated donor grafts adversely affected OS in multivariate analysis. Survival at 5 years for subjects with none, 1, 2, or 3 of these risk factors were 41% (range, 36%-47%), 32% (range, 27%-37%), 25% (range, 19%-31%), and 3% (range, 0%-11%), respectively (P < .0001).